LeMaitre Vascular (LMAT) Stock Could Be 16% Overvalued After Q3 Earnings

LeMaitre Vascular has delivered a strong multi year share price gain, and with the stock last closing at US$80.89 the live question is whether that level is supported by the cash the business can generate. Recent news around earnings quality and acquisitions adds more moving parts to the story, which puts the focus squarely on what the company’s cash flows may be worth today.

• Over the past 3 years the stock has returned 71.3%, which puts real pressure on the idea that the current valuation is still grounded in its underlying cash generation.
• Recent results highlighted higher net sales and a higher dividend, helped by an acquisition and offset by the absence of a prior year tax credit, which can affect how durable investors think earnings and future cash flows might be.
• If you'd rather focus on earnings, this one's for you. See what LeMaitre Vascular's 29.2x P/E says about the price.

The issue now is whether LeMaitre Vascular's current share price fairly reflects the intrinsic value suggested by its projected cash flows under a Discounted Cash Flow (DCF) approach.

If you want to stress test this same cash flow question beyond LeMaitre Vascular, line it up against companies in 39 high quality undervalued stocks

Has LeMaitre Vascular Run Too Far on Cash Flow?

The Discounted Cash Flow (DCF) model here uses a 2 Stage Free Cash Flow to Equity approach to line up LeMaitre Vascular’s cash generation against its share price. Latest twelve month free cash flow sits at about $67.8 million and the projections point to modestly growing cash flows over the next decade rather than a sharp ramp up. For a business already producing positive free cash flow, that implies a steadier, more mature profile rather than a high risk turnaround story.

On those assumptions, the DCF output suggests the estimated intrinsic value comes in meaningfully below the current trading level of US$80.89. The recent Q3 update, with higher net sales, a raised dividend and the B. Braun asset acquisition, helps explain why the market is willing to pay up relative to what the cash flow model implies today. You can test how that trade off between price and projected cash stacks up against other stocks in the same tool. Find out what LeMaitre Vascular could be worth using our Discounted Cash Flow (DCF) estimate.

The LeMaitre Vascular Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where LeMaitre Vascular's cash flow puzzle leaves off, by laying out the specific paths for growth, margins and earnings that would need to play out for the stock to be worth materially more or materially less than today. They live on Simply Wall St's Community page. Instead of a single output from a ratio or model, they spell out the future that figure rests on so you can track whether reality is matching that story over time.

One of the top community narratives on LeMaitre Vascular: 39% undervalued

"Relocalization of logistics through seven new or enlarged warehouses in Billerica, Madrid, Paris, Toronto, London, Dublin and Warsaw, combined with go direct transitions in markets such as Poland…"

Discover why this Narrative puts LeMaitre Vascular at 39% undervalued.

Before acting on LeMaitre Vascular's valuation, there is one more piece to check

Price, profits and projections only tell part of the story, because the people steering LeMaitre Vascular and the way their incentives are set up can strongly shape what happens next. See who runs LeMaitre Vascular and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com